<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ivermectin treatment in humans for reducing malaria transmission - de Souza, DK - 2021 | Cochrane Library</title> <meta content="Ivermectin treatment in humans for reducing malaria transmission - de Souza, DK - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013117.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ivermectin treatment in humans for reducing malaria transmission - de Souza, DK - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013117.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013117.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Ivermectin treatment in humans for reducing malaria transmission" name="citation_title"/> <meta content="Dziedzom K de Souza&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Ghana" name="citation_author_institution"/> <meta content="ddesouza@noguchi.ug.edu.gh" name="citation_author_email"/> <meta content="Rebecca Thomas&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="John Bradley" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="Clemence Leyrat" name="citation_author"/> <meta content="London School of Hygiene &amp; Tropical Medicine" name="citation_author_institution"/> <meta content="Daniel A Boakye" name="citation_author"/> <meta content="University of Ghana" name="citation_author_institution"/> <meta content="Joseph Okebe" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD013117.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/06/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013117.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013117.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013117.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antiparasitic Agents [*administration &amp; dosage, adverse effects, blood]; Bias; Burkina Faso [epidemiology]; Data Analysis; Incidence; Ivermectin [*administration &amp; dosage, adverse effects, blood]; Malaria [epidemiology, prevention &amp; control, *transmission]; *Mosquito Control; Pilot Projects; Prevalence; Randomized Controlled Trials as Topic" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013117.pub2&amp;doi=10.1002/14651858.CD013117.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013117\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013117\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","ko","ms","hr","fa","pl","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD013117.pub2",title:"Ivermectin treatment in humans for reducing malaria transmission",firstPublishedDate:"Jun 29, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013117.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013117.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013117.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013117.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013117.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013117.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013117.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013117.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013117.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013117.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9909 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013117.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-sec-0067"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-sec-0044"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-sec-0061"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/appendices#CD013117-sec-0071"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/references#riskOfBias2"> Risk of bias </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ivermectin treatment in humans for reducing malaria transmission</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#CD013117-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Dziedzom K de Souza</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#CD013117-cr-0005">Rebecca Thomas</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#CD013117-cr-0006">John Bradley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#CD013117-cr-0007">Clemence Leyrat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#CD013117-cr-0008">Daniel A Boakye</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information#CD013117-cr-0009">Joseph Okebe</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information/en#CD013117-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 June 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013117.pub2">https://doi.org/10.1002/14651858.CD013117.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013117-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013117-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013117-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013117-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013117-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013117-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013117-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013117-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013117-abs-0001" lang="en"> <section id="CD013117-sec-0001"> <h3 class="title" id="CD013117-sec-0001">Background</h3> <p>Malaria is transmitted through the bite of <i>Plasmodium‐</i> infected adult female <i>Anopheles</i> mosquitoes. Ivermectin, an anti‐parasitic drug, acts by killing mosquitoes that are exposed to the drug while feeding on the blood of people (known as blood feeds) who have ingested the drug. This effect on mosquitoes has been demonstrated by individual randomized trials. This effect has generated interest in using ivermectin as a tool for malaria control. </p> </section> <section id="CD013117-sec-0002"> <h3 class="title" id="CD013117-sec-0002">Objectives</h3> <p>To assess the effect of community administration of ivermectin on malaria transmission.</p> </section> <section id="CD013117-sec-0003"> <h3 class="title" id="CD013117-sec-0003">Search methods</h3> <p>We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, Science Citation index ‐ expanded, the World Health Organization (WHO) International Clinical Trials Registry Platform, ClinicalTrials.gov, and the National Institutes of Health (NIH) RePORTER database to 14 January 2021. </p> <p>We checked the reference lists of included studies for other potentially relevant studies, and contacted researchers working in the field for unpublished and ongoing trials. </p> </section> <section id="CD013117-sec-0004"> <h3 class="title" id="CD013117-sec-0004">Selection criteria</h3> <p>We included cluster‐randomized controlled trials (cRCTs) that compared ivermectin, as single or multiple doses, with a control treatment or placebo given to populations living in malaria‐endemic areas, in the context of mass drug administration. Primary outcomes were prevalence of malaria parasite infection and incidence of clinical malaria in the community. </p> </section> <section id="CD013117-sec-0005"> <h3 class="title" id="CD013117-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data on the number of events and the number of participants in each trial arm at the time of assessment. For rate data, we noted the total time at risk in each trial arm. To assess risk of bias, we used Cochrane's RoB 2 tool for cRCTs. We documented the method of data analysis, any adjustments for clustering or other covariates, and recorded the estimate of the intra‐cluster correlation (ICC) coefficient. </p> <p>We re‐analysed the trial data provided by the trial authors to adjust for cluster effects. We used a Poisson mixed‐effect model with small sample size correction, and a cluster‐level analysis using the linear weighted model to adequately adjust for clustering.  </p> </section> <section id="CD013117-sec-0006"> <h3 class="title" id="CD013117-sec-0006">Main results</h3> <p>We included one cRCT and identified six ongoing trials. </p> <p>The included cRCT examined the incidence of malaria in eight villages in Burkina Faso, randomized to two arms. Both trial arms received a single dose of ivermectin 150 µg/kg to 200 µg/kg, together with a dose of albendazole. The villages in the intervention arm received an additional five doses of ivermectin, once every three weeks. Children were enrolled into an active cohort, in which they were repeatedly screened for malaria infection.  </p> <p>The primary outcome was the cumulative incidence of uncomplicated malaria in a cohort of children aged five years and younger, over the 18‐week study. We judged the study to be at high risk of bias, as the analysis did not account for clustering or correlation between participants in the same village. </p> <p>The study did not demonstrate an effect of Ivermectin on the cumulative incidence of uncomplicated malaria in the cohort of children over the 18‐week study (risk ratio 0.86, 95% confidence interval (CI) 0.62 to 1.17; P = 0.2607; very low‐certainty evidence). </p> </section> <section id="CD013117-sec-0007"> <h3 class="title" id="CD013117-sec-0007">Authors' conclusions</h3> <p>We are uncertain whether community administration of ivermectin has an effect on malaria transmission, based on one trial published to date. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013117-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013117-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013117-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013117-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013117-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013117-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013117-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013117-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013117-abs-0014">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD013117-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013117-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013117-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013117-abs-0002" lang="en"> <h3>Malaria control using ivermectin</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to find out if giving the drug ivermectin to entire communities could reduce malaria transmission. We examined all relevant studies to answer this question, and found one relevant study. </p> <p><b>Key messages</b> </p> <p>It is not possible to say at this point if treating an entire community with ivermectin reduces malaria. Several research studies are in progress; we anticipate they will provide more answers in the future. </p> <p><b>What was studied in the review?</b> </p> <p>Malaria is a disease transmitted to humans through the bite of mosquitoes infected with <i>Plasmodium</i> parasites. It results in nearly half a million deaths every year. Ivermectin is a drug that is given to whole communities to control the parasites that are responsible for elephantiasis and river blindness. It has been observed that ivermectin can kill mosquitoes when they feed on the blood of people who have taken this medication. Therefore, it is believed that by giving this drug to whole communities, it will kill many mosquitoes, and could reduce malaria transmission. </p> <p>In this review, we assessed whether treating entire communities with ivermectin would reduce malaria transmission. We looked for studies from different sources, and only included studies that took place in communities with malaria, and that randomly assigned groups of people to ivermectin or a control, which could be a placebo or standard community drug treatments. We wanted to know if the treatment influenced the occurrence of malaria in the community. </p> <p><b>What are the main results of the review?</b> </p> <p>One study met the inclusion criteria. This study included eight villages in Burkina Faso, which were randomly assigned to receive ivermectin or a control. All villages received ivermectin, as part of the scheduled control of lymphatic filariasis. In addition, the treatment villages received five more doses of ivermectin, once every three weeks. The effect of ivermectin on malaria was measured in children younger than five years of age. In these children, the treatment did not show a notable difference in the presence of malaria between the treatment and control groups (very low‐certainty evidence). </p> <p>Therefore, it is not possible to say at this point if the treatment of entire communities with ivermectin has an effect on reducing malaria. Several studies are currently ongoing; we anticipate they will provide more answers in the future. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>We searched for studies published up to 14 January 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013117-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013117-sec-0067"></div> <h3 class="title" id="CD013117-sec-0068">Implications for practice</h3> <section id="CD013117-sec-0068"> <p>Although ivermectin has been demonstrated to reduce the lifespan of <i>Anopheles</i> mosquitoes (<a href="./appendices#CD013117-sec-0072">Appendix 1</a>), we do not know if community administration of ivermectin has an effect on malaria transmission. </p> <p>The available evidence on the effect of ivermectin on malaria transmission comes from one published trial (<a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a>).  The intervention did not show an effect in reducing the cumulative incidence of uncomplicated malaria. Therefore, we are uncertain whether community administration of ivermectin reduces malaria transmission. </p> </section> <h3 class="title" id="CD013117-sec-0069">Implications for research</h3> <section id="CD013117-sec-0069"> <p>The results of this trial, published in the Lancet, were contested based on differences in the analytical protocol used in presenting the primary outcome results (<a href="./references#CD013117-bbs2-0027" title="BradleyJ , MoultonLH , HayesR . Analysis of the RIMDAMAL trial. Lancet2019;394(10203):1005-6.">Bradley 2019</a>; <a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a> (<a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a> Authors’ reply)). It is important that ongoing trials consider and adopt a consistent protocol for analysis in cRCTs to improve our confidence in the effectiveness of ivermectin in malaria transmission. </p> <p>While children under five years of age are considered most vulnerable to disease, transmission is more likely to be sustained via the older population, who are typically asymptomatic carriers (<a href="./references#CD013117-bbs2-0025" title="BousemaT , OkellL , FelgerI , DrakeleyC . Asymptomatic malaria infections: detectability, transmissibility and public health relevance. Nature Reviews Microbiology2014;12(12):833-40.">Bousema 2014</a>; <a href="./references#CD013117-bbs2-0054" title="LindbladeKA , SteinhardtL , SamuelsA , KachurSP , SlutskerL . The silent threat: asymptomatic parasitemia and malaria transmission. Expert Review of Anti-infective Therapy2013;11(6):623-39.">Lindblade 2013</a>). Other trials reporting on the incidence and prevalence of infection would be useful in addressing the question of possible herd effect in the community. </p> <p>There are a number of trials in progress addressing the question of whether community administration of ivermectin reduces malaria transmission; the results will be included in updates of this review when available (<a href="./references#CD013117-bbs2-0021" title="RabinovichR , ChaccourC . BOHEMIA - Broad One Health Endectocide-based Malaria Intervention in Africa. www.isglobal.org/en/-/bohemia (accessed 12 May 2021). ">Rabinovich ongoing</a>; <a href="./references#CD013117-bbs2-0019" title="NCT04844905. Adjunctive Ivermectin Mass Drug Administration for Malaria Control (MATAMAL). https://clinicaltrials.gov/ct2/show/NCT04844905 (first posted 14 April 2021). ">NCT04844905 (MATAMAL)</a>; <a href="./references#CD013117-bbs2-0016" title="NCT03074435. Insecticide resistance management in Burkina Faso and Côte d'Ivoire (REACT). https://clinicaltrials.gov/ct2/show/NCT03074435 (first posted 8 March 2017). ">NCT03074435 (REACT)</a>; <a href="./references#CD013117-bbs2-0017" title="NCT03576313. Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination (MASSIV). https://clinicaltrials.gov/ct2/show/NCT03576313 (first posted 3 July 2018). ">NCT03576313 (MASSIV)</a>; <a href="./references#CD013117-bbs2-0018" title="NCT03967054. Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II). https://clinicaltrials.gov/ct2/show/NCT03967054 (first posted 30 May 2019). ">NCT03967054 (RIMDAMAL II)</a>; <a href="./references#CD013117-bbs2-0020" title="PrachumsriJ . A novel vector control measure to combat the spread of artemisinin resistance in the Greater Mekong Subregion. https://federalreporter.nih.gov/Projects/Details/?projectId=893768 (accessed 12 May 2021). ">PR150881</a>). See details in <a href="./references#CD013117-sec-0107" title="">Characteristics of ongoing studies</a>.  </p> <p>There is some uncertainty about what entomological outcomes are critical for making public health decisions and; recommendations, and how these should be measured. Comparative data from ongoing trials could help address this. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013117-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013117-sec-0008"></div> <div class="table" id="CD013117-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ivermectin versus control in humans to reduce malaria transmission</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ivermectin treatment in humans for reducing malaria transmission</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children living in malaria‐endemic areas </p> <p><b>Setting:</b>   villages in Burkina Faso<br/><b>Intervention:</b> single dose ivermectin 150 μg/kg to 200 μg/kg + 400 mg albendazole + 5 additional doses of ivermectin </p> <p><b>Comparison:</b> single dose ivermectin 150 μg/kg to 200 μg/kg + 400 mg albendazole </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p><b>Outcome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p> </p> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p> </p> <p><b>Number of participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard community MDA programmes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with repeated ivermectin MDA (95% CI)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of clinical malaria </b><br/><i>Follow‐up: 18 weeks</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2460 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>344 fewer per 1000 (from 935 fewer to 418 more­)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio (RR) 0.86<br/>(0.62 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590 (1 cRCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not repeat mass ivermectin administration reduces malaria incidence. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>Follow‐up: 18 weeks</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 more per 1000 (0 fewer to 32 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.63 (1.00 to 2.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2712 (1 cRCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>d,e</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not repeat mass ivermectin administration results in more adverse events. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>MDA</b> : mass drug administration; <b>cRCT</b> : cluster‐randomized controlled trial; <b>RR:</b> risk ratio. </p> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><sup>a</sup>Downgraded by two levels for risk of bias: due to bias arising from the timing of identification and recruitment of individual participants, and bias in the selection of the reported result.<br/><sup>b</sup>Downgraded by one level for imprecision: a small number of clusters, CIs span from fewer to more episodes of malaria.<br/><sup>c</sup>Downgraded by one level for indirectness: outcome was uncomplicated malaria, measured in children only.<br/><sup>d</sup>Downgraded by two levels for risk of bias: bias arising from the timing of identification and recruitment of individual participants, and bias in the selection of the reported result.<br/><sup>e</sup>Downgraded by one level for imprecision: low number of events and the CIs meet the line of no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013117-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013117-sec-0009"></div> <p>Malaria is an important vector‐borne disease, with an estimated 229 million cases and 409,000 deaths annually (<a href="./references#CD013117-bbs2-0081" title="World Health Organization. World Malaria Report 2020. www.who.int/malaria/publications/i/item/9789240015791 (accessed 12 May 2021).">WHO 2020</a>). It is caused by infection with the <i>Plasmodium</i> parasite. <i>Plasmodium falciparum and Plasmodium vivax </i> are the main<i> Plasmodium </i>species that cause persistent blood‐stage infections in humans, which last several weeks and months (<a href="./references#CD013117-bbs2-0022" title="AshleyEA , WhiteNJ . The duration of Plasmodium falciparum infections. Malaria Journal2014;13:500.">Ashley 2014</a>). In sub‐Saharan Africa, the main mosquito species responsible for transmission are <i>Anopheles</i> <i>gambiae sensu stricto</i> , <i>An funestus</i> , and <i>An arabiensis</i> . <i>An gambiae sensu stricto</i> is considered the most efficient of the malaria vectors, and preferentially feeds on humans (<a href="./references#CD013117-bbs2-0046" title="HaySI , GuerraCA , TatemAJ , NoorAM , SnowRW . The global distribution and population at risk of malaria: past, present, and future. Lancet Infectious Diseases2004;4(6):327-36. [PMID: 15172341]">Hay 2004</a>). </p> <p>Preventing mosquito bites is key to controlling malaria infection, and the use of long‐lasting insecticide‐treated bed nets (LLINs) and indoor residual spraying (IRS) with insecticides are central to this strategy (<a href="./references#CD013117-bbs2-0052" title="KilleenGF . Characterizing, controlling and eliminating residual malaria transmission. Malaria Journal2014;13:330.">Killeen 2014</a>; <a href="./references#CD013117-bbs2-0068" title="RussellTL , BeebeNW , CooperRD , LoboNF , BurkotTR . Successful malaria elimination strategies require interventions that target changing vector behaviours. Malaria Journal2013;12:56.">Russell 2013</a>). About 57% of people living in sub‐Saharan Africa now have access to a treated bed net (<a href="./references#CD013117-bbs2-0079" title="World Health Organization. World Malaria Report 2019. www.who.int/malaria/publications/world-malaria-report-2019/en/ (accessed 06 February 2020).">WHO 2019a</a>). Compared to estimates at the beginning of the century, the global incidence of malaria cases and deaths has significantly declined, with a 44% reduction in deaths in the World Health Organization (WHO) African region (<a href="./references#CD013117-bbs2-0081" title="World Health Organization. World Malaria Report 2020. www.who.int/malaria/publications/i/item/9789240015791 (accessed 12 May 2021).">WHO 2020</a>)<i>.</i> It is estimated that vector control interventions contributed to averting over 600 million clinical cases between 2000 and 2015 (<a href="./references#CD013117-bbs2-0023" title="BhattS , WeissDJ , CameronE , BisanzioD , MappinB , DalrympleU , et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature2015;526(7572):207-11.">Bhatt 2015</a>). </p> <p>Although progress in malaria control has slowed, the significant reduction in disease burden has prompted optimism for progress towards elimination in areas where reductions have been substantial, and for accelerating control measures to prevent a resurgence in transmission  (<a href="./references#CD013117-bbs2-0081" title="World Health Organization. World Malaria Report 2020. www.who.int/malaria/publications/i/item/9789240015791 (accessed 12 May 2021).">WHO 2020</a>). The large scale use of drugs and insecticides for elimination also raises concerns about increasing resistance to interventions considered the mainstay of control strategies. Insecticide resistance can manifest as changing vector behaviour in response to insecticide exposure, such as insecticide avoidance, outdoor biting preferences, and early exit behaviour by indoor‐feeding vectors (<a href="./references#CD013117-bbs2-0052" title="KilleenGF . Characterizing, controlling and eliminating residual malaria transmission. Malaria Journal2014;13:330.">Killeen 2014</a>; <a href="./references#CD013117-bbs2-0071" title="SougoufaraS , DiédhiouSM , DoucouréS , DiagneN , SembénePM , HarryM , et al. Biting by Anopheles funestus in broad daylight after use of long-lasting insecticidal nets: a new challenge to malaria elimination. Malaria Journal2014;13:125.">Sougoufara 2014</a>; <a href="./references#CD013117-bbs2-0076" title="ThomsenEK , KoimbuG , PulfordJ , Jamea-MaiasaS , UraY , KevenJB , et al. Mosquito behavior change after distribution of bednets results in decreased protection against malaria exposure. Journal of Infectious Diseases2017;215(5):790-7.">Thomsen 2017</a>). These vector behaviour changes reduce the effectiveness of vector control interventions. </p> <p>Additional interventions and strategies are clearly needed to sustain the gains made  (<a href="./references#CD013117-bbs2-0040" title="FeachemRG , ChenI , AkbariO , Bertozzi-VillaA , BhattS , BinkaF , et al. Malaria eradication within a generation: ambitious, achievable, and necessary. Lancet September 21, 2019;394(10203):1056-112.">Feachem 2019</a>; <a href="./references#CD013117-bbs2-0080" title="WHO Strategic Advisory Group on Malaria Eradication. Malaria eradication: benefits, future scenarios and feasibility. Executive summary. www.who.int/publications-detail/strategic-advisory-group-malaria-eradication-executive-summary (accessed 23 August 2019).">WHO 2019b</a>), and contain the spread of resistant vectors and parasites (<a href="./references#CD013117-bbs2-0032" title="ChurcherTS , LissendenN , GriffinJT , WorrallE , RansonH . The impact of pyrethroid resistance on the efficacy and effectiveness of bednets for malaria control in Africa. eLife2016;5:pii: e16090. [PMID: 27547988]">Churcher 2016</a>; <a href="./references#CD013117-bbs2-0067" title="RiveronJM , OsaeM , Egyir-YawsonA , IrvingH , IbrahimSS , WondjiCS . Multiple insecticide resistance in the major malaria vector Anopheles funestus in southern Ghana: implications for malaria control. Parasites &amp; Vectors2016;9(1):504. [PMID: 27628765]">Riveron 2016</a>). </p> <p>Given that a competent vector needs to live long enough to allow parasite development in the vector and subsequent transmission to a human host, reducing the survival and fitness of mosquitoes is important for the control of malaria transmission. The incubation period of <i>P falciparum</i> in the mosquito is between 12 and 18 days, at temperatures of about 24 °C (<a href="./references#CD013117-bbs2-0024" title="BlanfordJI , BlanfordS , CraneRG , MannME , PaaijmansKP , SchreiberKV , et al. Implications of temperature variation for malaria parasite development across Africa. Scientific Reports2013;3:1300.">Blanford 2013</a>). Furthermore, the reproductive cycle  of the mosquito, from blood feeding, blood meal digestion, egg maturation, to laying eggs, is shorter than the period of parasite development in the mosquito (<a href="./references#CD013117-bbs2-0033" title="ClementsAN . The Biology of Mosquitoes. Development, Nutrition, and Reproduction. London: Chapman &amp; Hall, 1992.">Clements 1992</a>). In <i>An gambiae</i> mosquitoes, the reproductive cycles could be as short as two days (<a href="./references#CD013117-bbs2-0066" title="QuiñonesML , LinesJD , ThomsonMC , JawaraM , MorrisJ , GreenwoodBM . Anopheles gambiae gonotrophic cycle duration, biting and exiting behaviour unaffected by permethrin-impregnated bednets in the Gambia. Medical and Veterinary Entomology1997;11(1):71-8.">Quiñones 1997</a>). Thus, female mosquitoes that live long enough to transmit parasites are more likely to have achieved reproductive success (<a href="./references#CD013117-bbs2-0073" title="SyVE , AgnewP , SidobreC , MichalakisY . Reduced survival and reproductive success generates selection pressure for the dengue mosquito Aedes aegypti to evolve resistance against infection by the microsporidian parasite Vavraia culicis. Evolutionary Applications2014;7(4):468-79.">Sy 2014</a>). </p> <p>Therefore, increasing the mortality rate of infected mosquitoes could significantly reduce the risk of transmission. One such method is the use of systemic insecticides or endectocides (used for the control of both endoparasites and ectoparasites). Ivermectin, a microfilaricide used for the control of veterinary and human helminths, but toxic to mosquitoes, has shown great potential (<a href="./references#CD013117-bbs2-0006" title="DeruaYA , KisinzaWN , SimonsenPE . Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus. Parasites &amp; Vectors2015;8:130. ">Derua 2015</a>). </p> <section id="CD013117-sec-0010"> <h3 class="title" id="CD013117-sec-0010">Description of the condition</h3> <p>Malaria transmission involves stages of growth and development in both humans and the mosquito vector. Strategies to control transmission are either preventive or therapeutic, and target parasite stages in humans or the mosquito vector (<a href="./references#CD013117-bbs2-0045" title="GravesPM , ChoiL , GelbandH , GarnerP . Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD008152. [DOI: 10.1002/14651858.CD008152.pub5]">Graves 2018</a>; <a href="./references#CD013117-bbs2-0069" title="SinclairD , ZaniB , DoneganS , OlliaroP , GarnerP . Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD007483. [DOI: 10.1002/14651858.CD007483.pub2]">Sinclair 2009</a>). </p> <p>Interventions against the mosquito vector rely on the biting and resting behaviours of mosquitoes (<a href="./references#CD013117-bbs2-0064" title="PaaijmansKP , ThomasMB . The influence of mosquito resting behaviour and associated microclimate for malaria risk. Malaria Journal2011;10:183.">Paaijmans 2011</a>). For example, insecticides on LLINs and IRS are designed for contact with the mosquito while indoors. They do not affect the parasite directly, but shorten the lifespan of the mosquito vector, thus, they interrupt the progression of the parasite cycle.  </p> <p>Interventions intended to have an impact on malaria transmission must be delivered on a large scale, for effect. These mass drug treatment campaigns have been implemented in the past as part of malaria elimination programmes (<a href="./references#CD013117-bbs2-0060" title="NájeraJA , González-SilvaM , AlonsoPL . Some lessons for the future from the Global Malaria Eradication Programme (1955-1969). PLoS Medicine2011;8(1):e1000412.">Nájera 2011</a>). Mass drug administration (MDA) involves treating entire populations in a geographical area with a therapeutic dose of a drug, regardless of the presence of symptoms, and without the need to determine infection status. Following reductions in the global malaria burden, there has been renewed interest in MDA to reduce malaria transmission (<a href="./references#CD013117-bbs2-0061" title="NewbyG , HwangJ , KoitaK , ChenI , GreenwoodB , vonSeidleinL , et al. Review of mass drug administration for malaria and its operational challenges. American Journal of Tropical Medicine and Hygiene2015;93(1):125-34.">Newby 2015</a>; <a href="./references#CD013117-bbs2-0065" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>). </p> </section> <section id="CD013117-sec-0011"> <h3 class="title" id="CD013117-sec-0011">Description of the intervention</h3> <p>Ivermectin is a broad‐spectrum, anti‐parasitic drug, used extensively for the treatment of a number of parasites in animals and humans (<a href="./references#CD013117-bbs2-0029" title="BurgRW , MillerBM , BakerEE , BirnbaumJ , CurrieSA , HartmanR , et al. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrobial Agents and Chemotherapy1979;15(3):361-7.">Burg 1979</a>). In humans, it is mainly used in the treatment of onchocerciasis and lymphatic filariasis (<a href="./references#CD013117-bbs2-0028" title="BrownKR , RicciFM , OttesenEA . Ivermectin: effectiveness in lymphatic filariasis. Parasitology2000;121(Suppl):S133-46.">Brown 2000</a>; <a href="./references#CD013117-bbs2-0034" title="CuppEW , SauerbreyM , RichardsF . Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan®) monotherapy. Acta Tropica2011;120(Suppl 1):S100-8.">Cupp 2011</a>), and is delivered through mass treatment campaigns (<a href="./references#CD013117-bbs2-0055" title="MakundeWH , KamugishaLM , MassagaJJ , MakundeRW , SavaelZX , AkidaJ , et al. Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis. Filaria Journal2003;2(1):15.">Makunde 2003</a>; <a href="./references#CD013117-bbs2-0059" title="MolyneuxDH , BradleyM , HoeraufA , KyelemD , TaylorMJ . Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends in Parasitology2003;19(11):516-22.">Molyneux 2003</a>). </p> <p>Ivermectin binds selectively and strongly to glutamate‐gated, chloride ion channels in muscles and nerve cells of invertebrates (<a href="./references#CD013117-bbs2-0058" title="MeyersJI , GrayM , KuklinskiW , JohnsonLB , SnowCD , Black WC 4th, et al. Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae. Journal of Experimental Biology2015;218(Pt 10):1478-86.">Meyers 2015</a>), and increases the permeability of their cell membrane to chloride ions. This process disrupts gamma‐aminobutyric acid (GABA)‐mediated neurosynaptic transmission in the central nervous system, resulting in flaccid paralysis and death (<a href="./references#CD013117-bbs2-0048" title="IkedaT . Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy. Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica2003;122(6):527-38. [PMID: 14639007]">Ikeda 2003</a>). While humans lack the specific glutamate‐gated channels that bind ivermectin, GABA‐gated channels are expressed that might cross‐react with ivermectin (<a href="./references#CD013117-bbs2-0082" title="WolstenholmeAJ . Glutamate-gated chloride channels. Journal of Biological Chemistry2012;287(48):40232-8.">Wolstenholme 2012</a>). Nonetheless, ivermectin is generally considered safe in humans, but toxic to organisms, such as mosquitoes. </p> <p>Ivermectin is readily absorbed in humans following ingestion (<a href="./references#CD013117-bbs2-0036" title="EdwardsG , DingsdaleA , HelsbyN , OrmeML , BreckenridgeAM . The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. European Journal of Clinical Pharmacology1988;35(6):681-4.">Edwards 1988</a>), and reaches peak plasma concentrations within four hours (<a href="./references#CD013117-bbs2-0038" title="ElkassabyMH . Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus. Tropical Medicine and Parasitology1991;42(2):79-81.">Elkassaby 1991</a>). However, it is quickly metabolized, with a half‐life of about 18 hours (<a href="./references#CD013117-bbs2-0057" title="Merck &amp; Co. Stromectol. FDA-approved package insert. www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s026lbl.pdf (accessed 30 May 2018).">Merck 2009</a>). Ivermectin is widely distributed in the body, mostly in fatty tissue (<a href="./references#CD013117-bbs2-0043" title="González CangaA , Sahagún PrietoAM , Diez LiébanaMJ , Fernández MartínezN , Sierra VegaM , García VieitezJJ . The pharmacokinetics and interactions of ivermectin in humans - a mini-review. American Association of Pharmaceutical Scientists Journal2008;10(1):42-6.">González Canga 2008</a>), and high concentrations have been observed in individuals with raised body mass index (<a href="./references#CD013117-bbs2-0013" title="OuédraogoAL , BastiaensGJ , TionoAB , GuelbéogoWM , KobylinskiKC , OuédraogoA , et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clinical Infectious Diseases2015;60(3):357-65. ">Ouédraogo 2015</a>). </p> <p>Ivermectin is not recommended in areas co‐endemic for <i>Loa loa</i>, as serious adverse reactions, including encephalopathy, extrapyramidal neurological signs, and in extreme cases, death, have been associated with its use (<a href="./references#CD013117-bbs2-0026" title="BoussinesqM , GardonM , KamgnoJ , PionSDS , Gardon-WendelN , Chippaux J-P. Relationships between the prevalence and intensity of Loa loa infection in the central province of Cameroon. Annals of Tropical Medicine and Parasitology2001;95(5):495-507.">Boussinesq 2001</a>; <a href="./references#CD013117-bbs2-0042" title="GardonJ , Gardon-WendelN , NgangueD , KamgnoJ , Chippaux J-P, BoussinesqM . Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa. Lancet1997;350(9070):18-20.">Gardon 1997</a>). Ivermectin is also not recommended for use by pregnant women (<a href="./references#CD013117-bbs2-0062" title="NicolasP , MaiaMF , BassatQ , KobylinskiKC , MonteiroW , RabinovichNR , et al. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. Lancet Global Health2020;8(1):e92-100.">Nicholas 2020</a>), and children younger than five years (<a href="./references#CD013117-bbs2-0039" title="FarrarJ , HotezP , JunghanssT , KangG , LallooD , WhiteNJ . Manson's Tropical Diseases. 23rd revised edition. UK: Elsevier Health Sciences, 2013.">Farrar 2013</a>). </p> <p>Ivermectin, the prototype endectocide, could have a role in mass treatment towards malaria elimination (<a href="./references#CD013117-bbs2-0005" title="ChaccourC , LinesJ , WhittyCJ . Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. Journal of Infectious Diseases2010;202(1):113-6. ">Chaccour 2010</a>; <a href="./references#CD013117-bbs2-0006" title="DeruaYA , KisinzaWN , SimonsenPE . Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus. Parasites &amp; Vectors2015;8:130. ">Derua 2015</a>). In order to accelerate the re‐purposing of ivermectin for malaria control and elimination, the WHO Global Malaria Programme published the preferred product characteristics for the use of endectocides as alternative interventions for controlling malaria transmission (<a href="./references#CD013117-bbs2-0077" title="World Health Organization. WHO preferred product characteristics: endectocide for malaria transmission control. apps.who.int/iris/bitstream/10665/255694/1/WHO-HTM-GMP-2017.10-eng.pdf?ua=1 (accessed 30 May 2018).">WHO 2017a</a>). A WHO technical consultation meeting recommended a 20% target reduction in malaria incidence for one month after MDA with a single round of ivermectin alone, or a significant reduction in malaria incidence for up to 12 months post‐intervention, if used in combination with artemisinin‐based combination therapy (ACT), and core vector control interventions for malaria control, as benchmarks for impact (<a href="./references#CD013117-bbs2-0078" title="World Health Organziation. Ivermectin for malaria transmission control: Technical consultation meeting report. www.who.int/malaria/mpac/mpac-sept2016-invermectin-session9.pdf?ua=1 (accessed 19 February 2021).">WHO 2017b</a>). </p> </section> <section id="CD013117-sec-0012"> <h3 class="title" id="CD013117-sec-0012">How the intervention might work</h3> <section id="CD013117-sec-0013"> <h4 class="title">Background</h4> <p>Ivermectin may reduce malaria transmission by shortening the lifespan of <i>Anopheles</i> mosquitoes exposed to the drug. For impact, the endectocidal effect must be sustained long enough to limit vector capacity. This can be achieved by giving higher doses, multiple doses, or using slow‐release preparations. However, the efficacy must be balanced against the risk of side effects, which may increase at higher doses (<a href="./references#CD013117-bbs2-0031" title="ChaccourC , HammannF , RabinovichNR . Ivermectin to reduce malaria transmission. I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malaria Journal2017;16(1):161.">Chaccour 2017</a>). Modelling studies have predicted that ivermectin could have a significant effect when used alone, or as a complementary intervention, in high transmission settings, in areas suitable for elimination, and may be most effective in areas with short transmission seasons (<a href="./references#CD013117-bbs2-0070" title="SlaterHC , FoyBD , KobylinskiK , ChaccourC , WatsonOJ , HellewellJ , et al. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Lancet Infectious Diseases2020;20(4):498-508. [DOI: 10.1016/S1473-3099(19)30633-4]">Slater 2020</a>). However, these models are based on data using laboratory‐reared mosquitoes, which may behave differently compared to wild mosquitoes (<a href="./references#CD013117-bbs2-0070" title="SlaterHC , FoyBD , KobylinskiK , ChaccourC , WatsonOJ , HellewellJ , et al. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Lancet Infectious Diseases2020;20(4):498-508. [DOI: 10.1016/S1473-3099(19)30633-4]">Slater 2020</a>). </p> <p>The endectocidal effect of ivermectin has been studied mainly by in vitro experiments, where lab‐reared mosquitos feed on ivermectin preparations via a membrane, and by in vivo studies, where mosquitos are allowed to feed on individuals' blood after they have taken oral ivermectin (<a href="./references#CD013117-bbs2-0002" title="Alout H,  Krajacich BJ, MeyersJI ,  Grubaugh ND,  Brackney DE,  Kobylinski KC, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malaria Journal2014;13:417. [DOI: 10.1186/1475-2875-13-417]">Alout 2014</a>; <a href="./references#CD013117-bbs2-0030" title="ChaccourCJ , RabinovichNR , SlaterH , CanavatiSE , BousemaT , LacerdaM , et al. Establishment of the Ivermectin Research for Malaria Elimination Network: updating the research agenda. Malaria Journal2015;14:243.">Chaccour 2015</a>; <a href="./references#CD013117-bbs2-0006" title="DeruaYA , KisinzaWN , SimonsenPE . Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus. Parasites &amp; Vectors2015;8:130. ">Derua 2015</a>; <a href="./references#CD013117-bbs2-0041" title="FoleyDH , BryanJH , LawrenceGW . The potential of ivermectin to control the malaria vector Anopheles farauti. Transactions of the Royal Society of Tropical Medicine and Hygiene2000;94(6):625-8.">Foley 2000</a>; <a href="./references#CD013117-bbs2-0008" title="KobylinskiKC , SyllaM , ChapmanPL , SarrMD , FoyBD . Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. American Journal of Tropical Medicine and Hygiene2011;85(1):3-5. [DOI: 10.4269/ajtmh.2011.11-0160]">Kobylinski 2011</a>). These studies demonstrate that the effect on mosquito mortality depends on the concentration of the drug in the blood, and the length of time drug concentrations remain above the lethal threshold. Sublethal effects of ivermectin have also been described, and include delayed re‐feed time, inhibiting the development of sporozoites, and reductions in fertility and egg hatch rates (<a href="./references#CD013117-bbs2-0031" title="ChaccourC , HammannF , RabinovichNR . Ivermectin to reduce malaria transmission. I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malaria Journal2017;16(1):161.">Chaccour 2017</a>).  Endectocidal and sub‐lethal outcomes in these studies have been reported in different formats, which creates a challenge for interpreting the effect. </p> </section> <section id="CD013117-sec-0014"> <h4 class="title">Systematic review of randomized controlled trials of ivermectin on mosquito mortality</h4> <p>The main Cochrane Review assesses the ability of ivermectin to reduce malaria transmission in the community. </p> <p>However, to assess the evidence behind the theory that ivermectin may have an effect on transmission, we briefly present our systematic review of the evidence that ivermectin has an effect on mosquito mortality. The full details of this systematic review are in <a href="./appendices#CD013117-sec-0072">Appendix 1</a>. </p> <p>Our inclusion criteria were randomized controlled trials (RCTs), conducted in healthy or malaria‐infected people, who were given oral ivermectin, and then either gave blood for membrane feeding, or allowed <i>Anopheles</i> species mosquitoes to feed directly on their arms. Studies measured cumulative mortality in the mosquitoes that were given access to the blood through membrane or direct feeding. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 14 January 2021, Issue 1 of 12) in the Cochrane Library (searched 14 January 2021), MEDLINE Pubmed (1946 to 14 January 2021), Embase Ovid, (1974 to 14 January 2021), and Web of Science (searched 14 January 2021), using the search terms: ivermectin or avermectin OR abamectin) AND Anopheles or mosquitocid*.  Two review authors (RT and JO) applied the inclusion criteria, and resolved any discrepancies by discussion. We used tabular data to summarise the outcome measures, as time points and mortality measures are highly variable. </p> <p>We identified 198 articles, five of which we included (<a href="./references#CD013117-bbs2-0005" title="ChaccourC , LinesJ , WhittyCJ . Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. Journal of Infectious Diseases2010;202(1):113-6. ">Chaccour 2010</a>; <a href="./references#CD013117-bbs2-0006" title="DeruaYA , KisinzaWN , SimonsenPE . Differential effect of human ivermectin treatment on blood feeding Anopheles gambiae and Culex quinquefasciatus. Parasites &amp; Vectors2015;8:130. ">Derua 2015</a>; <a href="./references#CD013117-bbs2-0011" title="MekuriawW , BalkewM , MessengerLA , YewhalawD , WoyessaA , MasseboF . The effect of ivermectin® on fertility, fecundity and mortality of Anopheles arabiensis fed on treated men in Ethiopia. Malaria Journal2019;18(1):537. [DOI: 10.1186/s12936-019-2988-3]">Mekuriaw 2019</a>; <a href="./references#CD013117-bbs2-0013" title="OuédraogoAL , BastiaensGJ , TionoAB , GuelbéogoWM , KobylinskiKC , OuédraogoA , et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clinical Infectious Diseases2015;60(3):357-65. ">Ouédraogo 2015</a>; <a href="./references#CD013117-bbs2-0015" title="SmitMR , OchomoEO , AljayyoussiG , KwambaiTK , Abong'oBO , ChenT , et al. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. Lancet Infected Diseases2016;18(6):615-26. ">Smit 2018</a>). In these studies, participants received oral ivermectin, after which, feeding experiments, using laboratory‐reared mosquitoes were conducted at set time points. The data showed that ivermectin has a large effect on mosquito mortality. This effect was associated with the dose of ivermectin, and the time between the ingestion of ivermectin and the feeding experiment. The effect also appeared to differ with mosquito species. A full summary of the results are presented in <a href="./appendices#CD013117-sec-0072">Appendix 1</a>. </p> <p>These findings are consistent with results from non‐randomized studies and ivermectin‐based MDAs against other mosquito‐borne diseases, such as lymphatic filariasis and onchocerciasis (<a href="./references#CD013117-bbs2-0002" title="Alout H,  Krajacich BJ, MeyersJI ,  Grubaugh ND,  Brackney DE,  Kobylinski KC, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malaria Journal2014;13:417. [DOI: 10.1186/1475-2875-13-417]">Alout 2014</a>; <a href="./references#CD013117-bbs2-0008" title="KobylinskiKC , SyllaM , ChapmanPL , SarrMD , FoyBD . Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages. American Journal of Tropical Medicine and Hygiene2011;85(1):3-5. [DOI: 10.4269/ajtmh.2011.11-0160]">Kobylinski 2011</a>; <a href="./references#CD013117-bbs2-0010" title="KositzC , TalinaJ , DiauJ , AsugeniR , WhitehornC , MabeyD , et al. Incidental mosquitocidal effect of an ivermectin mass drug administration on Anopheles farauti conducted for scabies control in the Solomon Islands. Transactions of the Royal Society of Tropical Medicine and Hygiene2017;111(3):97-101. [DOI: 10.1093/trstmh/trx025]">Kositz 2017</a>; <a href="./references#CD013117-bbs2-0074" title="SyllaM , KobylinskiKC , GrayM , ChapmanPL , SarrMD , RasgonJL , et al. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors. Malaria Journal2010;9:365.">Sylla 2010</a>; <a href="./references#CD013117-bbs2-0075" title="TeshRB , GuzmanH . Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin. American Journal of Tropical Medicine and Hygiene1990;43(3):229-33.">Tesh 1990</a>). </p> </section> </section> <section id="CD013117-sec-0015"> <h3 class="title" id="CD013117-sec-0015">Why it is important to do this review</h3> <p>There is a need for consensus in determining and defining outcome measures, methods for data analysis, and interpretation of results, to support decisions on the role of ivermectin in reducing malaria transmission in endemic populations. </p> <p>Our systematic review of five published studies showed a consistent and dose‐dependent effect of oral ivermectin treatment in humans on mosquito mortality (<a href="./appendices#CD013117-sec-0072">Appendix 1</a>). The studies also found that the observed mosquito mortality decreased as the time following ivermectin ingestion increased. Higher doses of ivermectin prolonged this effect, indicating a longer time of lethal concentration of ivermectin in the participants' blood. </p> <p>However, it is unclear whether this translates to reduced malaria transmission in endemic populations with wild mosquito vectors. In addition, the association between entomological endpoints, such as mosquito mortality and epidemiological indicators of impact, have not been validated. Other factors, such as bed net and insecticide usage, may affect the effectiveness of the intervention. </p> <p>Presently, there is one published trial on the effect of oral ivermectin on malaria transmission (<a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a>), and a number of <a href="./references#CD013117-bbs1-0003" title="">Ongoing studies</a>, with results expected in forthcoming years. This Cochrane Review provides a critique of the existing study, and highlights considerations for data analysis and presentation of results from subsequent trials, which will support a comprehensive update of this review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013117-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013117-sec-0016"></div> <p>To assess the effects of community administration of ivermectin on malaria transmission.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013117-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013117-sec-0017"></div> <section id="CD013117-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013117-sec-0019"> <h4 class="title">Types of studies</h4> <p>We included cluster‐randomized controlled trials (cRCTs) that compared mass administration of ivermectin to either infected or uninfected people versus control or standard mass drug regimes given to the whole population. Studies in which ivermectin was administered to animals were considered if there was simultaneous administration to the human population. </p> <p>Because the interventions considered in this review are at the community level, and the primary outcomes are population‐based malaria transmission indices, cRCTs are the most appropriate design to estimate unbiased causal effects at the level of communities, which are relevant for policymakers. </p> </section> <section id="CD013117-sec-0020"> <h4 class="title">Types of participants</h4> <p>We included adults and children living in malaria‐endemic areas.</p> </section> <section id="CD013117-sec-0021"> <h4 class="title">Types of interventions</h4> <section id="CD013117-sec-0022"> <h5 class="title">Intervention</h5> <p>Community mass drug administration (MDA) of ivermectin, given alone or together with other treatments, as single or multiple doses<b>.</b> </p> </section> <section id="CD013117-sec-0023"> <h5 class="title">Control</h5> <p>Placebo or no treatment.</p> <p>Other drugs administered as part of the usual MDA programme in the study area, as long as they were given to both intervention and control arms. Ivermectin was considered an appropriate control if this was part of the existing drug administration programme in the study area, and differed in dose from the intervention arm. </p> </section> </section> <section id="CD013117-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>The primary outcome measures were amended prior to the screening process to prioritize population‐based outcomes important for health policy. </p> <section id="CD013117-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013117-list-0001"> <li> <p>Prevalence of malaria parasite infection measured by microscopy, rapid diagnostic tests (RDTs), or molecular methods </p> </li> <li> <p>Incidence of clinical malaria, defined by symptoms with parasitaemia, detected by microscopy or RDTs </p> </li> </ul> </p> </section> <section id="CD013117-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013117-list-0002"> <li> <p>Mosquito mortality or survival at one, three, and nine days post‐treatment</p> </li> <li> <p>Mosquito density (number of each mosquito species in the study area, determined by trapping experiments) </p> </li> <li> <p><i>P falciparum</i> sporozoite rates (the proportion of female anopheline mosquitoes with <i>P falciparum</i> sporozoites in their salivary glands) </p> </li> <li> <p><i>P falciparum</i> oocyst rates (the proportion of female anopheline mosquitoes with <i>P falciparum</i> oocysts in their gut) </p> </li> </ul> </p> <section id="CD013117-sec-0027"> <h6 class="title">Adverse effects</h6> <p> <ul id="CD013117-list-0003"> <li> <p>Serious adverse effects (deaths, disability, hospitalization)</p> </li> <li> <p>Other adverse events, which may be local or systemic, but do not meet a classification as serious) </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD013117-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant studies regardless of date, language, or publication status. </p> <section id="CD013117-sec-0029"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Infectious Diseases Group (CIDG) Information Specialist searched the following databases, using the search terms detailed in <a href="./appendices#CD013117-sec-0096">Appendix 2</a>:  the CIDG Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL, 2021, Issue 1), in the Cochrane Library (searched 14 January 2021); MEDLINE PubMed (1966 to 14 January 2021); Embase OVID (1947 to 14 January 2021); Latin American Caribbean Health Sciences Literature (LILACS BIREME; 1982 to 14 January 2021); and Science Citation index ‐ Expanded Web of Science (1900 to 14 January 2021), We also searched the World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>); ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>); and the National Institutes of Health (NIH) RePORTER database (<a href="https://projectreporter.nih.gov/reporter.cfm" target="_blank">projectreporter.nih.gov/reporter.cfm</a>), using (ivermectin OR avermectin OR abamectin) and (malaria OR mosquit*).  </p> </section> <section id="CD013117-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of the included study for other potentially relevant studies. We contacted researchers working in the field to ask about unpublished and ongoing trials. </p> <p>We searched the MESA Track: a living database of research projects focusing on malaria eradication, to find unregistered trials in progress (<a href="http://www.malariaeradication.org/mesa-track" target="_blank">www.malariaeradication.org/mesa-track</a>; searched 8 February 2021). </p> </section> </section> <section id="CD013117-sec-0031"> <h3 class="title" id="CD013117-sec-0031">Data collection and analysis</h3> <section id="CD013117-sec-0032"> <h4 class="title">Selection of studies</h4> <p>Two review authors (DKD and JO) independently screened the titles and abstracts of the search results for potentially relevant studies, using predefined eligibility criteria. We reviewed the full‐text of reports identified through this screening, and resolved disagreements on eligibility by discussion. We considered duplicate publications from the same study as a single entry. We listed all studies excluded after full‐text assessment in a <a href="./references#CD013117-sec-0106" title="">Characteristics of excluded studies</a> table. The selection process is presented in a PRISMA diagram (<a href="#CD013117-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013117-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt=" PRISMA flow diagram detailing the database search results and study selection process" data-id="CD013117-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p> PRISMA flow diagram detailing the database search results and study selection process</p> </div> </div> </div> </section> <section id="CD013117-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (DKD and RT) independently extracted data using a pre‐tested extraction form, with differences in extracted data resolved in discussion with a third review contributor (Dr Birhanu Ayele). In order to evaluate causes of heterogeneity, we extracted data on study design; study population and setting (country); frequency of ivermectin administration; duration of follow‐up for both human and mosquito populations; and methods for ensuring comparability between sites in multisite studies. We also extracted estimates of outcomes of interest, together with their corresponding measures of precision for our meta‐analysis. </p> <p>For dichotomous variables, we extracted data on the number of events and the number of participants in each trial arm at the time of assessment. For rate data, we extracted the number of events in the treatment and comparison group, and the total time at risk in each trial arm. For cRCTs, we recorded the unit of randomization, the number of clusters, and the average size of each cluster. We documented details about adjustment for clustering or other covariates, such as the intra‐cluster correlation (ICC) coefficient. We contacted the study authors for additional information when this was unclear in the trial report. </p> </section> <section id="CD013117-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Four review authors (CL, RT, DKD, and JO) independently assessed the risk of bias of the included studies, using Cochrane's RoB 2 for cRCTs (<a href="./references#CD013117-bbs2-0037" title="EldridgeS , CampbellM , CampbellM , DrahotaA , GiraudeauB , HigginsJ , et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. Available from https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool (accessed 12 May 2021).">Eldridge 2021</a>). When there were differences in judgments, we came to a group consensus, including review authors RT, JO, and DKD. We used the ROB 2 tool for cRCTs Microsoft Word template, November 2020 version, to complete the assessment (<a href="./references#CD013117-bbs2-0072" title="SterneJAC , SavovićJ , PageMJ , ElbersRG , BlencoweNS , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898.">Sterne 2019</a>). We assessed the risk of bias for intention‐to‐treat effects for the primary outcomes, malaria incidence and adverse events. We assessed items under the following domains:  </p> <p> <ul id="CD013117-list-0004"> <li> <p>Risk of bias in the randomization process</p> </li> <li> <p>Bias in the timing of identification and recruitment of individual participants in relation to the timing of randomization </p> </li> <li> <p>Bias due to deviations from the intended interventions</p> </li> <li> <p>Bias due to missing outcome data</p> </li> <li> <p>Bias in the measurement of the outcome</p> </li> <li> <p>Bias in the selection of the reported result</p> </li> </ul> </p> <p>We reported the judgements as 'low', 'some concerns', or 'high'. We generated a summary risk of bias table based on our observations using the Risk‐of‐bias VISualization (robviz) tool (<a href="./references#CD013117-bbs2-0056" title="McGuinness, LA, HigginsJPT . Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Research Synthesis Methods2020;12:55-61. [DOI: 10.1002/jrsm.141]">McGuinness 2020</a>). The recorded consensus decisions are stored as supplemental data. We judged studies to have a high risk of bias when we judged one domain to be at high risk of bias, or where we found some concerns in multiple domains, unless we could justify a different judgment. </p> </section> <section id="CD013117-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>We compared the incidence of clinical malaria episodes by calculating the risk ratio and the mean difference in rates of episodes between treatment arms. We presented effect estimates with 95% confidence intervals (CIs). </p> <p>We compared the frequency of adverse events between treatment arms as absolute numbers, risk ratios, and risk differences with 95% CIs. </p> </section> <section id="CD013117-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>The search focused on cRCTs only, so we sought to account for clustering (at the level used for randomization) in the analysis, in order to obtain valid CIs and P values. For trials with a small number of clusters, we applied specific small sample corrections to avoid an inflation of the type I error rate, that is, a too high probability of showing a statistically significant intervention effect when there is none (<a href="./references#CD013117-bbs2-0050" title="KahanBC , ForbesG , AliY , JairathV , BremnerS , HarhayMO , et al. Increased risk of type I errors in cluster randomised trials with small or medium numbers of clusters: a review, reanalysis, and simulation study. Trials2016;17(1):438.">Kahan 2016</a>; <a href="./references#CD013117-bbs2-0053" title="LeyratC , MorganKE , LeurentB , KahanBC . Cluster randomized trials with a small number of clusters: which analyses should be used?International Journal of Epidemiology2017;47(1):321–31.">Leyrat 2017</a>). </p> <p>In the included trial, these considerations were ignored, hence, we re‐analysed the data using a Poisson mixed‐effects model with a small‐sample correction to compare rates of malaria episodes between clusters (units of randomization (<a href="./references#CD013117-bbs2-0051" title="KenwardMG , RogerJH . Small sample inference for fixed effects from restricted maximum likelihood. Biometrics1997;53(3):983-97. [DOI: 10.2307/2533558]">Kenward 1997</a>)). </p> <p>For repeated treatment given to the same participant, we analysed outcomes as count outcomes. We did not include the same participant's data in a meta‐analysis more than once, to avoid double‐counting. To account for variations in treatment effect between individual studies, we considered using a random‐effects model for any planned meta‐analysis. </p> </section> <section id="CD013117-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>We searched for discrepancies in the published data on participant numbers and percentage loss for each treatment group. When all randomized participants were accounted for, we conducted an intention‐to‐treat analysis. </p> </section> <section id="CD013117-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the baseline characteristics of included studies to determine the suitability of pooling the results in a meta‐analysis. We planned to regard heterogeneity as moderate if the I² statistic lay between 30% and 60%; substantial if it was between 59% and 90%; and considerable if it was between 75% and 100% (<a href="./references#CD013117-bbs2-0035" title="DeeksJJ , HigginsJP , Altman DG (editors) on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook .">Deeks 2017</a>). We would regard a Chi² test statistic with a P ≤ 0.10 to be indicative of statistically significant heterogeneity. We planned an exploration of clinical and methodological heterogeneity through consideration of the trial populations, methods, and interventions, and by visualization of trial results. When we found heterogeneity that was at least moderate, we planned a subgroup analysis to help identify any effect modification observed in the result. </p> </section> <section id="CD013117-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>We could not assess reporting bias since we only included one trial in the review. We assessed selective outcome reporting in the included trial as part of the risk of bias assessment. </p> </section> <section id="CD013117-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We only included one study in the review, but were able to obtain the primary data from the trial authors, which we re‐analyzed. </p> <p>When additional trial results become available, we will combine study data in a meta‐analysis, if feasible. When appropriate, we will combine studies with a fixed‐effect meta‐analysis model, based on the generic inverse‐variance approach. However, we will use a random‐effects model in the event of considerable heterogeneity (I<sup>2  </sup>statistic over 75%). We will present results for unadjusted cRCTs separately if we do not have enough information to adjust them for clustering. For outcomes of repeated dosing, we will stratify the analysis by the number of rounds of treatment. The primary analysis will pool data regardless of risk of bias.  </p> </section> <section id="CD013117-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not conduct a subgroup analysis. In future revisions, we will evaluate heterogeneity in results by subgroup analysis based on malaria transmission intensity (i.e. low‐ or high‐density infection areas), population treated and assessed for malaria (i.e. children versus adults), and ivermectin dose and frequency of administration (single or multiple doses versus annual or biannual administration). </p> </section> <section id="CD013117-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>For each study, we analyzed the primary outcome using a Poisson regression model with a random effect, to account for clustering at the level of the unit of randomization, with the Kenward‐Roger correction for small samples (<a href="./references#CD013117-bbs2-0051" title="KenwardMG , RogerJH . Small sample inference for fixed effects from restricted maximum likelihood. Biometrics1997;53(3):983-97. [DOI: 10.2307/2533558]">Kenward 1997</a>). To assess the robustness of the results to different modelling assumptions, we re‐analysed the trial data using: </p> <p> <ul id="CD013117-list-0005"> <li> <p>a cluster‐level analysis of the difference in rates of malaria episodes using a weighted t‐test, with weights accounting for the variability in cluster size. This approach is very robust when only a few clusters are randomized.  </p> </li> <li> <p>a random‐effect Poisson regression without a small sample correction, to check the impact on power of the small sample correction </p> </li> <li> <p>generalized estimating equations (GEEs) with an exchangeable correlation structure, with and without a small sample correction, to estimate population‐average, rather than cluster‐specific effects (<a href="./references#CD013117-bbs2-0047" title="HuangS , FieroMH , BellML . Generalized estimating equations in cluster randomized trials with a small number of clusters: review of practice and simulation study. Clinical Trials (London, England)2016;13(4):445-9.">Huang 2016</a>). </p> </li> </ul> </p> <p>When additional trial results become available, we will conduct a sensitivity analysis to assess the effects of restricting the analysis to trials with low or low plus some concerns in the risk of bias assessment.  </p> </section> <section id="CD013117-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of the evidence using the GRADE approach (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006404.pub3/references#CD006404-bbs2-0055" target="_blank">Schünemann 2013</a>). We appraised the certainty of the evidence in relation to the following criteria: study design, risk of bias, inconsistency, indirectness, imprecision, other considerations (including publication bias). </p> <p>We generated a summary of findings table for our primary outcomes when data was available and adverse events, using <a href="./references#CD013117-bbs2-0044" title="McMaster University (developed by Evidence Prime, Inc.)GRADEpro Guideline Development Tool. Version accessed 12 May 2021. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), 2020. Available at gradepro.org.">GRADEpro GDT</a> (<a href="./references#CD013117-bbs2-0044" title="McMaster University (developed by Evidence Prime, Inc.)GRADEpro Guideline Development Tool. Version accessed 12 May 2021. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.), 2020. Available at gradepro.org.">GRADEpro GDT</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013117-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013117-sec-0044"></div> <section id="CD013117-sec-0045"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD013117-sec-0105" title="">Characteristics of included studies</a>; <a href="./references#CD013117-sec-0106" title="">Characteristics of excluded studies</a>; <a href="./references#CD013117-sec-0107" title="">Characteristics of ongoing studies</a>. </p> <section id="CD013117-sec-0046"> <h4 class="title">Results of the search</h4> <p>We identified 119 records through our searches. We removed duplicates, leaving 112 records and we screened all articles for possible inclusion. After title and abstract screening, we excluded 91 ineligible trials.  We assessed 21 full‐text articles for eligibility and excluded 14 articles for the following reasons: two trials did not have the required outcomes, four had the wrong study design, and eight were not cluster‐randomized. One trial met the inclusion criteria with six identified ongoing trials (<a href="#CD013117-fig-0001">Figure 1</a>). </p> </section> <section id="CD013117-sec-0047"> <h4 class="title">Included studies</h4> <p>One study met the inclusion criteria (<a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a>). This was a cluster‐randomized pilot study conducted in Burkina Faso, a malaria‐endemic country with highly seasonal transmission (<a href="./references#CD013117-bbs2-0063" title="Ouédraogo A, Tiono AB, Diarra A, Sanon S, Yaro JB, OuedraogoE , et al. Malaria morbidity in high and seasonal malaria transmission area of Burkina Faso. PLoS One2013;8(1):e50036.">Ouédraogo 2013</a>). Study villages were the unit of randomization, and a total of eight villages were included in the study; four villages per arm. This trial was registered as a pilot study, and powered as such. </p> <p>Participants in both trial arms received a single dose of ivermectin 150 µg/kg to 200 µg/kg, together with a dose of albendazole, as part of the scheduled control of lymphatic filariasis. Villages in the intervention arm received an additional five doses of ivermectin, one every three weeks (<a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a>). The primary outcome, cumulative malaria incidence, was measured in a cohort of children, aged five years and younger. Malaria prevalence was not measured in this trial. </p> <p>In total, 563 (20.7%) of the study village population were excluded from MDA for various reasons; height less than the required 90 cm, pregnant women, nursing mothers within the first week of birth, and people with a history of travel to a <i>Loa loa</i> endemic area. Of the children in the primary outcome monitoring cohort, 21% (121 of 590) met the criteria to receive ivermectin. </p> <p>The primary outcome was the cumulative incidence of uncomplicated malaria, measured in the cohort of 590 children (263 children in the control villages and 327 children in the intervention villages) over an 18‐week intervention period. An uncomplicated malaria episode was defined as a child with a temperature of at least 38.0°C, or a history of fever in the preceding 24 hours, and a positive malaria rapid diagnostic test. Other measured outcomes were: the passive case detection of the number and type of adverse events following ivermectin ingestion, and serological reactivity to anopheline salivary gland protein. Entomological outcomes included human biting rate, sporozoite rate, entomological inoculation rate, and mosquito parity. </p> <p>We contacted the study authors for the use of the primary data for re‐analysis. The lead author kindly supplied and approved the use of the primary data. </p> </section> <section id="CD013117-sec-0048"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 studies, and listed the reasons in the <a href="./references#CD013117-sec-0106" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD013117-sec-0049"> <h4 class="title">Ongoing studies</h4> <p>We identified six ongoing studies in the trials registers (<a href="./references#CD013117-bbs2-0021" title="RabinovichR , ChaccourC . BOHEMIA - Broad One Health Endectocide-based Malaria Intervention in Africa. www.isglobal.org/en/-/bohemia (accessed 12 May 2021). ">Rabinovich ongoing</a>; <a href="./references#CD013117-bbs2-0019" title="NCT04844905. Adjunctive Ivermectin Mass Drug Administration for Malaria Control (MATAMAL). https://clinicaltrials.gov/ct2/show/NCT04844905 (first posted 14 April 2021). ">NCT04844905 (MATAMAL)</a>; <a href="./references#CD013117-bbs2-0016" title="NCT03074435. Insecticide resistance management in Burkina Faso and Côte d'Ivoire (REACT). https://clinicaltrials.gov/ct2/show/NCT03074435 (first posted 8 March 2017). ">NCT03074435 (REACT)</a>; <a href="./references#CD013117-bbs2-0017" title="NCT03576313. Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination (MASSIV). https://clinicaltrials.gov/ct2/show/NCT03576313 (first posted 3 July 2018). ">NCT03576313 (MASSIV)</a>; <a href="./references#CD013117-bbs2-0018" title="NCT03967054. Repeat Ivermectin Mass Drug Administrations for MALaria Control II (RIMDAMAL II). https://clinicaltrials.gov/ct2/show/NCT03967054 (first posted 30 May 2019). ">NCT03967054 (RIMDAMAL II)</a>; <a href="./references#CD013117-bbs2-0020" title="PrachumsriJ . A novel vector control measure to combat the spread of artemisinin resistance in the Greater Mekong Subregion. https://federalreporter.nih.gov/Projects/Details/?projectId=893768 (accessed 12 May 2021). ">PR150881</a>). See details in <a href="./references#CD013117-sec-0107" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD013117-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>Please see <a href="#CD013117-fig-0002">Figure 2</a> for the risk of bias summary. A supplementary file containing details of the RoB 2 consensus judgments is available on request from the CIDG editorial base.  </p> <div class="figure" id="CD013117-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Summary of risk of bias for each outcomes, across domains" data-id="CD013117-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary of risk of bias for each outcomes, across domains</p> </div> </div> </div> <p>For the primary outcome of malaria incidence, we judged the study to have an overall high risk of bias, due to the high risk of bias in the identification or recruitment of participants in the cRCT, and in the selection of the reported result. The enrolment of individual participants took place after randomization, and we judged that knowledge of the decision could have influenced participation. Baseline imbalances in bed net use could represent differential recruitment, however, with a few clusters, the imbalances could be due to chance (<a href="#CD013117-tbl-0002">Table 1</a>). We judged there to be a high risk of bias due to multiple eligible measurements of malaria incidence, and multiple analyses of the data. </p> <div class="table" id="CD013117-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of the children, clusters, and households</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control N = 263</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention N = 327</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Standardized mean difference (%)*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Individual‐level covariates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120 (45.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159 (48.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bednet use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>229 (87.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314 (96.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age 4 to 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 92 (35.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136 (41.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Height ≥ 90 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (23.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (21.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age (median (Q1 to Q3)) , years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cluster‐level covariate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of included children per village </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43, 48, 58, 114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35, 66, 98, 128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Households</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 106</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 127</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Household size (median (Q1 to Q3))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>*The standardized mean difference is a measure quantifying the imbalance between groups. A variable with a difference &gt; 10% between groups is considered unbalanced. </p> </div> </div> <p>We had some concerns due to deviations from the intended interventions. The participants were not blinded to the intervention. However, the dropout rates were low with 79% of participants in the control villages and 75% of the participants in the intervention villages. No whole clusters were analysed in a group different from their allocation.  </p> <p>We judged there to be a low risk of bias arising from the randomization process, along with adequate allocation concealment. We judged there to be a low risk of bias due to low levels of missing outcome data, with 14 out of the 263 children recruited from the control villages and 10 of the 327 children from the intervention villages lost to follow‐up. We judged there to be a low risk of bias in the measurement of the main outcome; this was standardized and the outcome assessors were blinded to the intervention received.  See <a href="#CD013117-tbl-0003">Table 2</a> for a summary of the RoB 2 judgments and justifications for malaria incidence. </p> <div class="table" id="CD013117-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RoB 2 for cluster‐randomized trials summary of judgments: malaria Incidence </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.1. Was the allocation sequence random?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Sealed envelopes containing the words 'treatment' and 'control' were mixed in a container and randomly pulled from the container by a community health worker representing each village. There were large baseline imbalances in bednet use; however, these differences could be due to chance.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.2. Was the allocation sequence concealed until clusters were enrolled and assigned to interventions?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.3. Were there baseline imbalances that suggest a problem with the randomization process?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PN</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.1. Were all the individual participants identified before randomization of clusters?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Enrolment of households took place after the randomization of villages. Knowledge of multiple mass drug administrations (MDA) could affect participant decision‐making. Heads of households discussed with the chiefs whether to be involved in the study or not. See protocol pg 25. The baseline imbalance in bednet use and the number of children could represent differential recruitment. However, this could be compatible with chance with cluster randomization.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.2. If N/PN/NI to 1b.1: is it likely that selection of individual participants was affected by knowledge of the intervention?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.3. Were there baseline imbalances that suggest differential identification or recruitment of individual participants between arms?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PN</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1a. Were participants aware that they were in a trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>The study was blinded only to the outcome assessor, who was allowed access only to the coded group and participant data when doing the initial analyses. The participants or carers were not blinded to the intervention. Deviations from the intended intervention were not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1b. If Y/PY/NI to 2.1a: were participants aware of their assigned intervention during the trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.2. Were carers and trial personnel aware of participants' assigned intervention during the trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.3. If Y/PY/NI to 2.1 or 2.2: were there deviations from the intended intervention that arose because of the trial context?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.4. If Y/PY to 2.3: were these deviations from intended intervention unbalanced between groups and likely to have affected the outcome?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.5a. Were any clusters or participants analysed in a group different from the one to which they were assigned?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.6. Was an appropriate analysis used to estimate the effect of assignment to intervention?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.7. If N/PN/NI to 2.6: was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.1a. Were outcome data available for all, or nearly all, clusters randomized?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Data were available for all clusters randomized. 14 children were lost to follow‐up from the control group, and 10 from the intervention group. Data were available in all clusters.  </p> <p>“Participation in mass drug administrations in the intervention group started at 1080 (75%) of 1447 enrolled village residents and dropped slightly over subsequent administrations: 1056 (73%) in the second, 1051 (73%) in the third, 1060 (73%) in the fourth, 1037 (72%) in the fifth, and 1020 (70%) in the sixth administration. In the control group, 999 (79%) of 1265 people participated in the mass drug administration.” There was a fall in coverage in the intervention arm, however, as the control had no placebo, it is difficult to say if the deviations arose because of the trial context. They did not state whether they compared a per‐protocol analysis or ITT analysis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.1b. Were outcome data available for all, or nearly all, participants within clusters?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.2. If N/PN/NI to 3.1: are the proportions of missing outcome data and reasons for missing outcome data similar across intervention groups?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.3. If N/PN/NI to 3.1: is there evidence that results were robust to the presence of missing outcome data?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.1. Was the method of measuring the outcome inappropriate?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Low risk</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>The method of measuring malaria incidence is acceptable in public health malaria trials.  The outcome (cumulative incidence of uncomplicated malaria episodes in children ≤ 5 years of age) was assessed by active case surveillance in study villages 2X/week – a malaria episode was defined as ≥ 38.0 °C fever or a history of fever in the last 24 hours + positive rapid diagnostic test for <i>Plasmodium falciparum</i>. There was an objective protocol for measurement. The study was blinded only to the outcome assessor, who was allowed access only to the coded group and participant data when doing the initial analyses. The outcome assessor was defined as the assessor conducting the analysis. It was unlikely that the awareness of the outcome assessor would have influenced the outcome measurement. <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.2. Could measurement or ascertainment of the outcome have differed between intervention groups?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.3a. If N/PN/NI to 4.1 and 4.2: were outcome assessors aware that a trial was taking place?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.3b. If Y/PY/NI to 4.3a: were outcome assessors aware of the intervention received by study participants?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.1. Were the data that produced this result analysed in accordance with a prespecified analysis plan that was finalized before unblinded outcome data were available for analysis?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>There was a prespecified analysis plan, however, it did not detail the method of cluster adjustment used.  </p> <p>They used clinical malaria ‐definition uncomplicated only.</p> <p>Malaria episode was defined by a temperature of 38.0°C or higher (0.5°C was added to each thermometer recording to account for axillary readings) or history of fever in the last 24 h, and a positive rapid diagnostic test (SD Bioline Malaria Ag P.f/Pan; Alere, Inc) for <i>Plasmodium</i> . Rapid diagnostic tests were considered positive if any test line appeared (histidine‐rich protein II antigen of <i>P falciparum</i> , or common lactate dehydrogenase of <i>Plasmodium sp</i>, or both), and incidence data were not modified in response to these results. </p> <p> </p> <p>As demonstrated in the review, the method of adjustment can influence the results.</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Is the numerical result being assessed likely to have been selected, on the basis of the results, from...</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.2. ...multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.3 ...multiple eligible analyses of the data?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Y: Yes; N: No, PY: Probably Yes, PN: Probably No, NI: No Information</p> </div> </div> <p>For the outcome adverse events, we also judged it at an overall high risk of bias, due to the identification of participants after randomization, and the selection of the reported result. We noted an additional concern in the reporting of the significance of the adverse event risk difference. The trial authors did not report the P value for the adverse event risk difference of 1.21, 95% CI 0.04 to 2.38; the values suggest a significant increase in adverse events. However, as we judge the risk ratio to be the primary effect estimate, this did not affect our overall risk of bias judgment. See  <a href="#CD013117-tbl-0004">Table 3</a> for a summary of the RoB 2 judgments and justifications for adverse events. </p> <div class="table" id="CD013117-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">RoB 2 for cluster‐randomized trials summary of judgments: adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.1. Was the allocation sequence random?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Sealed envelopes containing the words 'treatment' and 'control' were mixed in a container and randomly pulled from the container by a community health worker representing each village. There were large baseline imbalances in bednet use; however, these differences could be due to chance.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.2. Was the allocation sequence concealed until clusters were enrolled and assigned to interventions?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.3. Were there baseline imbalances that suggest a problem with the randomization process?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PN</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.1. Were all the individual participants identified before randomization of clusters?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Enrolment of households took place after the randomization of villages. Knowledge of multiple mass drug administrations (MDA) could affect participant decision‐making. Heads of households discussed with the chiefs whether to be involved in the study or not. See protocol pg 25. The baseline imbalance in bednet use, and the number of children could represent differential recruitment. However, this could be compatible with chance with cluster randomization.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.2. If N/PN/NI to 1b.1: is it likely that selection of individual participants was affected by knowledge of the intervention?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PY</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.3. Were there baseline imbalances that suggest differential identification or recruitment of individual participants between arms?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1a. Were participants aware that they were in a trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>The study was blinded only to the outcome assessor, who was allowed access only to the coded group and participant data when doing the initial analyses. The participants or carers were not blinded to the intervention. Deviations from the intended intervention were not reported. Although 14 children were lost to follow‐up from the control group and 10 from the intervention groups. <br/>“Participation in mass drug administrations in the intervention groups started at 1080 (75%) of 1447 enrolled village residents and dropped slightly over subsequent administrations: 1056 (73%) in the second, 1051 (73%) in the third, 1060 (73%) in the fourth, 1037 (72%) in the fifth, and 1020 (70%) in the sixth administration. In the control group, 999 (79%) of 1265 people participated in the mass drug administration.” There was a fall in coverage in the intervention arm; however, as the control had no placebo, it is difficult to say if the deviations arose because of the trial context. They did not state whether they compared a per‐protocol analysis or ITT analysis. It is very unlikely that entire clusters were analysed in the wrong group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1b. If Y/PY/NI to 2.1a: were participants aware of their assigned intervention during the trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.2. Were carers and trial personnel aware of participants' assigned intervention during the trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.3. If Y/PY/NI to 2.1 or 2.2: were there deviations from the intended intervention that arose because of the trial context?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.4. If Y/PY to 2.3: were these deviations from intended intervention unbalanced between groups and likely to have affected the outcome?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.5a. Were any clusters or participants analysed in a group different from the one to which they were assigned?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.6. Was an appropriate analysis used to estimate the effect of assignment to intervention?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.7. If N/PN/NI to 2.6: was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.1a. Were outcome data available for all, or nearly all, clusters randomized?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Data were available for all clusters randomized. 14 children were lost to follow‐up from the control group and 10  from the intervention group. Data were available in all clusters. <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.1b. Were outcome data available for all, or nearly all, participants within clusters?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.2. If N/PN/NI to 3.1: are the proportions of missing outcome data and reasons for missing outcome data similar across intervention groups?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.3. If N/PN/NI to 3.1: is there evidence that results were robust to the presence of missing outcome data?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.1. Was the method of measuring the outcome inappropriate?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Low risk</p> <p> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>The method of measuring malaria incidence is acceptable in public health malaria trials. There was an objective protocol for measurement. The study was blinded only to the outcome assessor, who was allowed access only to the coded group and participant data when doing the initial analyses.  The outcome assessor was defined as the assessor conducting the analysis. It was unlikely that the awareness of the outcome assessor would have influenced the outcome measurement.  </p> <p>Adverse events were reported to the study team. Adverse events were objective measures.  They included all adverse events, whether related directly to the intervention or not. They were then analysed as being related to the intervention or not by the blinded study team. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.2. Could measurement or ascertainment of the outcome have differed between intervention groups?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.3a. If N/PN/NI to 4.1 and 4.2: were outcome assessors aware that a trial was taking place?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.3b. If Y/PY/NI to 4.3a: were outcome assessors aware of the intervention received by study participants?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.4. If Y/PY/NI to 4.3b: could assessment of the outcome have been influenced by knowledge of intervention received?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PN</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.5. If Y/PY/NI to 4.4: is it likely that assessment of the outcome was influenced by knowledge of intervention received?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.1. Were the data that produced this result analysed in accordance with a prespecified analysis plan that was finalized before unblinded outcome data were available for analysis?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Statistical Analysis Plan and protocol available. Participants had repeated adverse events with multiple categorizations of severity and relation to the intervention. The data were not cluster adjusted. The analysis was by events rather than by the individuals. No adjustment of the result.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Is the numerical result being assessed likely to have been selected, on the basis of the results, from...</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.2.  ...multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.3. ...multiple eligible analyses of the data?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Y: yes; N: no, PY: probably yes, PN: probably no, NI: no information</p> </div> </div> </section> <section id="CD013117-sec-0051"> <h3 class="title" id="CD013117-sec-0051">Effects of interventions</h3> <p>See: <a href="./full#CD013117-tbl-0001"><b>Summary of findings 1</b> Ivermectin versus control in humans to reduce malaria transmission</a> </p> <section id="CD013117-sec-0052"> <h4 class="title">Primary outcomes</h4> <section id="CD013117-sec-0053"> <h5 class="title">Prevalence of malaria parasite infection</h5> <p>No included trials reported the effect of mass administration of ivermectin on the prevalence of malaria parasite infection.  </p> </section> <section id="CD013117-sec-0054"> <h5 class="title">Incidence of clinical malaria</h5> <p><a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a> reported 648 malaria episodes in the intervention group (327 children) and 647 episodes in the control group (263 children). We present the results using different models of analysis appropriate for cRCTs with small number of clusters. </p> <p>The risk ratio (RR) of malaria episodes between the intervention and the control arms, when estimated using the Poisson mixed‐effects model with small sample size correction, was 0.86 (95% CI 0.62 to 1.17; P = 0.2607). The mean difference (MD) in the rate of malaria episodes between arms when using the Poisson mixed model with small‐sample correction was ‐0.35 (95% CI ‐1.05 to 0.36; P = 0.2617). The mean difference in malaria episodes in the cluster level analysis using weights accounting for variability in cluster size  was ‐0.34 (95% CI ‐0.90 to 0.22; P = 0.2829). <a href="#CD013117-fig-0003">Figure 3</a> demonstrates the overlap of CIs of the malaria rates between each cluster. </p> <div class="figure" id="CD013117-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Distribution of the average number of malaria episodes per cluster." data-id="CD013117-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Distribution of the average number of malaria episodes per cluster.</p> </div> </div> </div> </section> </section> <section id="CD013117-sec-0055"> <h4 class="title">Secondary outcomes</h4> <section id="CD013117-sec-0056"> <h5 class="title">Mosquito mortality or survival</h5> <p>No included trials measured the effect of mass administration of ivermectin on mosquito mortality or survival. </p> </section> <section id="CD013117-sec-0057"> <h5 class="title">Mosquito density</h5> <p>No included trials measured the effect of mass administration of ivermectin on mosquito density. </p> </section> <section id="CD013117-sec-0058"> <h5 class="title"><i>P falciparum</i> sporozoite rates </h5> <p>The study authors did not share the sporozoites rate data for re‐analysis but reported in the published report that it was not noticeably different between groups. </p> <p>The reported weekly entomological inoculation rate was not different between the control and intervention arms (P = 0.956). The study authors did not report the effect size, nor did they share the data for reanalysis. </p> </section> <section id="CD013117-sec-0059"> <h5 class="title"><i>P falciparum</i> oocyst rates </h5> <p>No included trials measured the effect of mass administration of ivermectin on <i>p falciparum</i> oocyst rates. </p> </section> <section id="CD013117-sec-0060"> <h5 class="title">Adverse effects</h5> <p>The trial authors did not provide us with safety data for re‐analysis, so we reported on the trial results presented in the published report, which are unadjusted for the clustering effect. </p> <p>The reported risk of adverse events among all participants was higher in the intervention group than in the control group. The study reported 45 events (3%) from 1447 participants in the intervention group, and 24 events (2%) from 1265 in the control group. The risk ratio (RR) was 1.63, 95% CI 1.01 to 2.67; P = 0.060. Sixty‐nine adverse events occurred in 65 (2%) participants who reported one episode adverse event, and 4 (0.1%) participants who reported a second event. Thirty‐two (49%) of these adverse events were reported from the cohort of children. </p> <p>The study authors deemed the adverse events that were classified as possibly or probably related to the intervention as adverse reactions. There were five (0.3%) adverse reactions in the intervention group, and three (0.2%) in the control group. These included vomiting, pruritus, oedema in the limbs, and tremors. There were 20 (0.7%) deaths amongst all participants during the trial period, which were deemed unlikely or not related to the intervention. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013117-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013117-sec-0061"></div> <p>There is considerable interest in the use of ivermectin to complement existing malaria control interventions. Individual‐based studies using laboratory‐reared mosquitoes provide a proof‐of‐concept on the efficacy of ivermectin for mosquito mortality (<a href="./appendices#CD013117-sec-0072">Appendix 1</a>). Modelling studies suggest that ivermectin can reduce malaria transmission when used in combination with other antimalarials (<a href="./references#CD013117-bbs2-0070" title="SlaterHC , FoyBD , KobylinskiK , ChaccourC , WatsonOJ , HellewellJ , et al. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Lancet Infectious Diseases2020;20(4):498-508. [DOI: 10.1016/S1473-3099(19)30633-4]">Slater 2020</a>). However, currently, there is only one published cluster‐randomized controlled trial (cRCT) that has assessed the role of ivermectin in reducing malaria transmission (<a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a>). This trial was registered as a pilot study and powered as such. </p> <section id="CD013117-sec-0062"> <h3 class="title" id="CD013117-sec-0062">Summary of main results</h3> <p>We included one cluster‐randomized controlled trial (cRCT). The study was conducted in Burkina Faso, with eight villages randomized to two arms. Both trial arms received a single dose of ivermectin 150 µg/kg to 200 µg/kg, together with a dose of albendazole. Villages in the intervention arm received an additional five doses of ivermectin, one every three weeks. Children, aged five years and younger, were enrolled in an active cohort, in which they were repeatedly screened for malaria infection.  </p> <p>The primary outcome was the cumulative incidence of uncomplicated malaria in the cohort of children, over the 18‐week study. The study did not demonstrate an effect of ivermectin on the cumulative incidence of uncomplicated malaria in the cohort of children over the 18‐week study (risk ratio 0.86, 95% confidence interval (CI) 0.62 to 1.17;  P = 0.2607), although the study was underpowered to detect the true effect.  </p> </section> <section id="CD013117-sec-0063"> <h3 class="title" id="CD013117-sec-0063">Overall completeness and applicability of evidence</h3> <p>While models of potential effect have been used to inform possible applications of the drug, the study included in this Cochrane Review did not demonstrate an effect of ivermectin on the cumulative incidence of uncomplicated malaria. The benefits of the intervention could be detected through future adequately powered studies. There are a number of ongoing studies, which could improve our understanding of the effectiveness of this intervention (see <a href="./references#CD013117-sec-0107" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD013117-sec-0064"> <h3 class="title" id="CD013117-sec-0064">Quality of the evidence</h3> <p>We assessed the certainty of the evidence using the GRADE approach, and presented it in the <a href="./full#CD013117-tbl-0001">summary of findings Table 1</a>. </p> <p>There was very low‐certainty evidence about the efficacy of ivermectin in reducing the incidence of clinical malaria.  The effect estimate was based on a single trial with a high risk of bias. Bias arose from the timing of identification and recruitment of individual participants, and bias in the selection of the reported result. This study was conducted as part of the scheduled yearly mass treatment activities with ivermectin, which is relatively safe, and has been given in Burkina Faso since the early 2000s. Therefore, there may be potential biases due to participants' knowledge of the drug and response to the intervention, compared to participants who had not taken this drug before. Baseline imbalances in bed net use and the number of children could represent differential recruitment, although, this could also be compatible with chance with cluster randomization. The multiple possible analyses of the final result introduces bias.   </p> <p>We also downgraded due to imprecision, due to the small number of clusters and overlapping CIs. The effect is indirect, as the outcome was uncomplicated malaria, measured in children ≤ 5 years, most of whom would not have received the treatment due to the ≥ 90 cm height requirement.  </p> <p>We judged the certainty of the evidence about the safety of ivermectin to be very low because of imprecision, due to a low number of events and a CI that included no effect. </p> </section> <section id="CD013117-sec-0065"> <h3 class="title" id="CD013117-sec-0065">Potential biases in the review process</h3> <p>We re‐analysed the primary data. We investigated potential bias by conducting a sensitivity analysis using the three available approaches for analysis when there is a small sample size in a cluster‐randomized trial.  </p> <p>We included only cluster‐randomized trials, and this resulted in the exclusion of several cohort or cross over trials that reported some of the secondary outcomes. We have, however, included the RCT data in <a href="./appendices#CD013117-sec-0072">Appendix 1</a>. </p> </section> <section id="CD013117-sec-0066"> <h3 class="title" id="CD013117-sec-0066">Agreements and disagreements with other studies or reviews</h3> <p>There has been no other systematic review conducted on this topic. A narrative review by the <a href="./references#CD013117-bbs2-0049" title="BillingsleyP , BinkaF , ChaccourC , FoyB , GoldS , Gonzalez-SilvaM , et al, the Ivermectin Roadmappers. A roadmap for the development of ivermectin as a complementary malaria vector control tool. American Journal of Tropical Medicine and Hygiene2020;102(2s):3-24.">Ivermectin Roadmappers 2020</a> included <a href="./references#CD013117-bbs2-0001" title="FoyBD ,  Alout H,  SeamanJA ,  Rao S,  Magalhaes T,  WadeM , et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet2019;393(10180):1517-26. [DOI: 10.1016/S0140-6736(18)32321-3]FoyBD , AloutH , SeamanJA , RaoS , MagalhaesT , WadeM , et al. RIMDAMAL I de-identified data . Data on file (as supplied 10 March 2020) . FoyBD , RaoS , ParikhS , SlaterHC , DabiréRK . Analysis of the RIMDAMAL trial - Authors' reply. Lancet2019;394(10203):1006-7. NCT02509481. Repeat ivermectin mass drug administrations for control of malaria: a pilot safety and efficacy study. clinicaltrials.gov/show/nct02509481 (first posted 28 July 2015). ">Foy 2019</a> as the only study to demonstrate the effect of ivermectin MDA on malaria transmission. In the review they quoted a 20% reduction in malaria incidence in children &lt; 5 years old but acknowledge the debate over the statistical significance of these findings, which was highlighted as inappropriate (<a href="./references#CD013117-bbs2-0027" title="BradleyJ , MoultonLH , HayesR . Analysis of the RIMDAMAL trial. Lancet2019;394(10203):1005-6.">Bradley 2019</a>). For the mosquito lethal efficacy data, they included trials in which mosquitoes bloodfed on animal as well as human blood donors (<a href="./references#CD013117-bbs2-0049" title="BillingsleyP , BinkaF , ChaccourC , FoyB , GoldS , Gonzalez-SilvaM , et al, the Ivermectin Roadmappers. A roadmap for the development of ivermectin as a complementary malaria vector control tool. American Journal of Tropical Medicine and Hygiene2020;102(2s):3-24.">Ivermectin Roadmappers 2020</a>). This highlighted the variation in mosquito lethal effects for ivermectin, depending on the bloodmeal source. </p> <p>We re‐analysed the primary study data provided by the trial authors. The methods that we used for the re‐analysis to account for clustering are, to our knowledge, all the available methods for the analysis of cluster RCT's with a small sample size and all showed consistent results.  The consistent lack of effect in the reanalysis differs from the findings in the original publication. This lack of effect may be from a lack of power and not a lack of benefits from the intervention.  </p> <p>We cannot make a conclusive inference on the effect of ivermectin on malaria transmission based on this single trial. However, it highlights the importance of the process used in generating trial results for reported outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013117-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/urn:x-wiley:14651858:media:CD013117:CD013117-FIG-01" target="_blank"><b></b></a></p> </div><img alt=" PRISMA flow diagram detailing the database search results and study selection process" data-id="CD013117-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_t/tCD013117-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p> PRISMA flow diagram detailing the database search results and study selection process</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013117-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/urn:x-wiley:14651858:media:CD013117:CD013117-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Summary of risk of bias for each outcomes, across domains" data-id="CD013117-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_t/tCD013117-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Summary of risk of bias for each outcomes, across domains</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013117-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/urn:x-wiley:14651858:media:CD013117:CD013117-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Distribution of the average number of malaria episodes per cluster." data-id="CD013117-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_t/tCD013117-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Distribution of the average number of malaria episodes per cluster.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/media/CDSR/CD013117/image_n/nCD013117-FIG-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013117-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ivermectin versus control in humans to reduce malaria transmission</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ivermectin treatment in humans for reducing malaria transmission</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children living in malaria‐endemic areas </p> <p><b>Setting:</b>   villages in Burkina Faso<br/><b>Intervention:</b> single dose ivermectin 150 μg/kg to 200 μg/kg + 400 mg albendazole + 5 additional doses of ivermectin </p> <p><b>Comparison:</b> single dose ivermectin 150 μg/kg to 200 μg/kg + 400 mg albendazole </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p><b>Outcome</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p> </p> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p> </p> <p><b>Number of participants (studies)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard community MDA programmes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with repeated ivermectin MDA (95% CI)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of clinical malaria </b><br/><i>Follow‐up: 18 weeks</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2460 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>344 fewer per 1000 (from 935 fewer to 418 more­)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk ratio (RR) 0.86<br/>(0.62 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590 (1 cRCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not repeat mass ivermectin administration reduces malaria incidence. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p><i>Follow‐up: 18 weeks</i> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>19 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 more per 1000 (0 fewer to 32 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.63 (1.00 to 2.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2712 (1 cRCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>d,e</sup> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We are uncertain whether or not repeat mass ivermectin administration results in more adverse events. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>MDA</b> : mass drug administration; <b>cRCT</b> : cluster‐randomized controlled trial; <b>RR:</b> risk ratio. </p> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> <p><sup>a</sup>Downgraded by two levels for risk of bias: due to bias arising from the timing of identification and recruitment of individual participants, and bias in the selection of the reported result.<br/><sup>b</sup>Downgraded by one level for imprecision: a small number of clusters, CIs span from fewer to more episodes of malaria.<br/><sup>c</sup>Downgraded by one level for indirectness: outcome was uncomplicated malaria, measured in children only.<br/><sup>d</sup>Downgraded by two levels for risk of bias: bias arising from the timing of identification and recruitment of individual participants, and bias in the selection of the reported result.<br/><sup>e</sup>Downgraded by one level for imprecision: low number of events and the CIs meet the line of no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ivermectin versus control in humans to reduce malaria transmission</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013117-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of the children, clusters, and households</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control N = 263</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention N = 327</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Standardized mean difference (%)*</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Individual‐level covariates</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120 (45.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>159 (48.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bednet use</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>229 (87.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314 (96.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age 4 to 5 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 92 (35.0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>136 (41.6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Height ≥ 90 cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (23.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (21.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Age (median (Q1 to Q3)) , years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cluster‐level covariate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Number of included children per village </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43, 48, 58, 114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35, 66, 98, 128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Households</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 106</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N = 127</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Household size (median (Q1 to Q3))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*The standardized mean difference is a measure quantifying the imbalance between groups. A variable with a difference &gt; 10% between groups is considered unbalanced. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Baseline characteristics of the children, clusters, and households</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013117-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RoB 2 for cluster‐randomized trials summary of judgments: malaria Incidence </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.1. Was the allocation sequence random?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Sealed envelopes containing the words 'treatment' and 'control' were mixed in a container and randomly pulled from the container by a community health worker representing each village. There were large baseline imbalances in bednet use; however, these differences could be due to chance.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.2. Was the allocation sequence concealed until clusters were enrolled and assigned to interventions?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.3. Were there baseline imbalances that suggest a problem with the randomization process?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PN</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.1. Were all the individual participants identified before randomization of clusters?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Enrolment of households took place after the randomization of villages. Knowledge of multiple mass drug administrations (MDA) could affect participant decision‐making. Heads of households discussed with the chiefs whether to be involved in the study or not. See protocol pg 25. The baseline imbalance in bednet use and the number of children could represent differential recruitment. However, this could be compatible with chance with cluster randomization.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.2. If N/PN/NI to 1b.1: is it likely that selection of individual participants was affected by knowledge of the intervention?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.3. Were there baseline imbalances that suggest differential identification or recruitment of individual participants between arms?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PN</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1a. Were participants aware that they were in a trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>The study was blinded only to the outcome assessor, who was allowed access only to the coded group and participant data when doing the initial analyses. The participants or carers were not blinded to the intervention. Deviations from the intended intervention were not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1b. If Y/PY/NI to 2.1a: were participants aware of their assigned intervention during the trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.2. Were carers and trial personnel aware of participants' assigned intervention during the trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.3. If Y/PY/NI to 2.1 or 2.2: were there deviations from the intended intervention that arose because of the trial context?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.4. If Y/PY to 2.3: were these deviations from intended intervention unbalanced between groups and likely to have affected the outcome?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.5a. Were any clusters or participants analysed in a group different from the one to which they were assigned?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.6. Was an appropriate analysis used to estimate the effect of assignment to intervention?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.7. If N/PN/NI to 2.6: was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.1a. Were outcome data available for all, or nearly all, clusters randomized?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Data were available for all clusters randomized. 14 children were lost to follow‐up from the control group, and 10 from the intervention group. Data were available in all clusters.  </p> <p>“Participation in mass drug administrations in the intervention group started at 1080 (75%) of 1447 enrolled village residents and dropped slightly over subsequent administrations: 1056 (73%) in the second, 1051 (73%) in the third, 1060 (73%) in the fourth, 1037 (72%) in the fifth, and 1020 (70%) in the sixth administration. In the control group, 999 (79%) of 1265 people participated in the mass drug administration.” There was a fall in coverage in the intervention arm, however, as the control had no placebo, it is difficult to say if the deviations arose because of the trial context. They did not state whether they compared a per‐protocol analysis or ITT analysis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.1b. Were outcome data available for all, or nearly all, participants within clusters?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.2. If N/PN/NI to 3.1: are the proportions of missing outcome data and reasons for missing outcome data similar across intervention groups?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.3. If N/PN/NI to 3.1: is there evidence that results were robust to the presence of missing outcome data?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.1. Was the method of measuring the outcome inappropriate?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Low risk</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>The method of measuring malaria incidence is acceptable in public health malaria trials.  The outcome (cumulative incidence of uncomplicated malaria episodes in children ≤ 5 years of age) was assessed by active case surveillance in study villages 2X/week – a malaria episode was defined as ≥ 38.0 °C fever or a history of fever in the last 24 hours + positive rapid diagnostic test for <i>Plasmodium falciparum</i>. There was an objective protocol for measurement. The study was blinded only to the outcome assessor, who was allowed access only to the coded group and participant data when doing the initial analyses. The outcome assessor was defined as the assessor conducting the analysis. It was unlikely that the awareness of the outcome assessor would have influenced the outcome measurement. <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.2. Could measurement or ascertainment of the outcome have differed between intervention groups?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.3a. If N/PN/NI to 4.1 and 4.2: were outcome assessors aware that a trial was taking place?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.3b. If Y/PY/NI to 4.3a: were outcome assessors aware of the intervention received by study participants?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.1. Were the data that produced this result analysed in accordance with a prespecified analysis plan that was finalized before unblinded outcome data were available for analysis?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>There was a prespecified analysis plan, however, it did not detail the method of cluster adjustment used.  </p> <p>They used clinical malaria ‐definition uncomplicated only.</p> <p>Malaria episode was defined by a temperature of 38.0°C or higher (0.5°C was added to each thermometer recording to account for axillary readings) or history of fever in the last 24 h, and a positive rapid diagnostic test (SD Bioline Malaria Ag P.f/Pan; Alere, Inc) for <i>Plasmodium</i> . Rapid diagnostic tests were considered positive if any test line appeared (histidine‐rich protein II antigen of <i>P falciparum</i> , or common lactate dehydrogenase of <i>Plasmodium sp</i>, or both), and incidence data were not modified in response to these results. </p> <p> </p> <p>As demonstrated in the review, the method of adjustment can influence the results.</p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Is the numerical result being assessed likely to have been selected, on the basis of the results, from...</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.2. ...multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.3 ...multiple eligible analyses of the data?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Y: Yes; N: No, PY: Probably Yes, PN: Probably No, NI: No Information</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">RoB 2 for cluster‐randomized trials summary of judgments: malaria Incidence </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013117-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">RoB 2 for cluster‐randomized trials summary of judgments: adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.1. Was the allocation sequence random?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Sealed envelopes containing the words 'treatment' and 'control' were mixed in a container and randomly pulled from the container by a community health worker representing each village. There were large baseline imbalances in bednet use; however, these differences could be due to chance.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.2. Was the allocation sequence concealed until clusters were enrolled and assigned to interventions?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1a.3. Were there baseline imbalances that suggest a problem with the randomization process?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PN</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.1. Were all the individual participants identified before randomization of clusters?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Enrolment of households took place after the randomization of villages. Knowledge of multiple mass drug administrations (MDA) could affect participant decision‐making. Heads of households discussed with the chiefs whether to be involved in the study or not. See protocol pg 25. The baseline imbalance in bednet use, and the number of children could represent differential recruitment. However, this could be compatible with chance with cluster randomization.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.2. If N/PN/NI to 1b.1: is it likely that selection of individual participants was affected by knowledge of the intervention?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PY</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1b.3. Were there baseline imbalances that suggest differential identification or recruitment of individual participants between arms?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1a. Were participants aware that they were in a trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>The study was blinded only to the outcome assessor, who was allowed access only to the coded group and participant data when doing the initial analyses. The participants or carers were not blinded to the intervention. Deviations from the intended intervention were not reported. Although 14 children were lost to follow‐up from the control group and 10 from the intervention groups. <br/>“Participation in mass drug administrations in the intervention groups started at 1080 (75%) of 1447 enrolled village residents and dropped slightly over subsequent administrations: 1056 (73%) in the second, 1051 (73%) in the third, 1060 (73%) in the fourth, 1037 (72%) in the fifth, and 1020 (70%) in the sixth administration. In the control group, 999 (79%) of 1265 people participated in the mass drug administration.” There was a fall in coverage in the intervention arm; however, as the control had no placebo, it is difficult to say if the deviations arose because of the trial context. They did not state whether they compared a per‐protocol analysis or ITT analysis. It is very unlikely that entire clusters were analysed in the wrong group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.1b. If Y/PY/NI to 2.1a: were participants aware of their assigned intervention during the trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.2. Were carers and trial personnel aware of participants' assigned intervention during the trial?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.3. If Y/PY/NI to 2.1 or 2.2: were there deviations from the intended intervention that arose because of the trial context?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.4. If Y/PY to 2.3: were these deviations from intended intervention unbalanced between groups and likely to have affected the outcome?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.5a. Were any clusters or participants analysed in a group different from the one to which they were assigned?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.6. Was an appropriate analysis used to estimate the effect of assignment to intervention?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2.7. If N/PN/NI to 2.6: was there potential for a substantial impact (on the result) of the failure to analyse participants in the group to which they were randomized?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.1a. Were outcome data available for all, or nearly all, clusters randomized?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Some concerns</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Data were available for all clusters randomized. 14 children were lost to follow‐up from the control group and 10  from the intervention group. Data were available in all clusters. <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.1b. Were outcome data available for all, or nearly all, participants within clusters?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.2. If N/PN/NI to 3.1: are the proportions of missing outcome data and reasons for missing outcome data similar across intervention groups?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.3. If N/PN/NI to 3.1: is there evidence that results were robust to the presence of missing outcome data?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.1. Was the method of measuring the outcome inappropriate?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Low risk</p> <p> <br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>The method of measuring malaria incidence is acceptable in public health malaria trials. There was an objective protocol for measurement. The study was blinded only to the outcome assessor, who was allowed access only to the coded group and participant data when doing the initial analyses.  The outcome assessor was defined as the assessor conducting the analysis. It was unlikely that the awareness of the outcome assessor would have influenced the outcome measurement.  </p> <p>Adverse events were reported to the study team. Adverse events were objective measures.  They included all adverse events, whether related directly to the intervention or not. They were then analysed as being related to the intervention or not by the blinded study team. </p> <p> <br/> <br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4.2. Could measurement or ascertainment of the outcome have differed between intervention groups?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>N</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.3a. If N/PN/NI to 4.1 and 4.2: were outcome assessors aware that a trial was taking place?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.3b. If Y/PY/NI to 4.3a: were outcome assessors aware of the intervention received by study participants?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.4. If Y/PY/NI to 4.3b: could assessment of the outcome have been influenced by knowledge of intervention received?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PN</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.5. If Y/PY/NI to 4.4: is it likely that assessment of the outcome was influenced by knowledge of intervention received?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.1. Were the data that produced this result analysed in accordance with a prespecified analysis plan that was finalized before unblinded outcome data were available for analysis?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PY</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Statistical Analysis Plan and protocol available. Participants had repeated adverse events with multiple categorizations of severity and relation to the intervention. The data were not cluster adjusted. The analysis was by events rather than by the individuals. No adjustment of the result.<br/>  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Is the numerical result being assessed likely to have been selected, on the basis of the results, from...</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.2.  ...multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>5.3. ...multiple eligible analyses of the data?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Y</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Y: yes; N: no, PY: probably yes, PN: probably no, NI: no information</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">RoB 2 for cluster‐randomized trials summary of judgments: adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013117.pub2/full#CD013117-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013117.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013117-note-0037">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013117-note-0028">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013117-note-0034">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD013117-note-0025">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD013117-note-0019">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013117-note-0022">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013117-note-0031">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD013117-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013117-note-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013117-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013117\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013117\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013117\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013117\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013117\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013117.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013117.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013117.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013117.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013117.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727605428"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013117.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727605431"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013117.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb0276fae936d',t:'MTc0MDcyNzYwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 